Difference between revisions of "Eluvixtamab (AMG-330)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | Bispecific T-cell engager | + | Bispecific T-cell engager antibody that engages CD33 and CD3 |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' AMG 330 | + | *'''Code name:''' AMG-330 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
| − | [[Category:Anti-CD33 | + | [[Category:Anti-CD33-CD3 bispecific antibodies]] |
| − | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 00:14, 18 October 2023
Mechanism of action
Bispecific T-cell engager antibody that engages CD33 and CD3
Also known as
- Code name: AMG-330